

Docket No.: MXI-352US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Christine Margarete Unger *et al.*

Application No.: 10/539,402

Confirmation No.: 6754

Filed: December 22, 2005

Art Unit: 1649

For: NEUROPILIN-1 INHIBITORS

Examiner: S. Gucker

STATEMENT PURSUANT TO 37 CFR 1.821

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

In connection with the Sequence Listing submitted concurrently herewith in the above-identified patent application, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. the content of the electronically filed Sequence Listing is submitted in accordance with 37 C.F.R. § 1.821(e).

Dated: August 18, 2009

Respectfully submitted,

Electronic signature: /Andrew T. Wilkins/
Andrew T. Wilkins, Ph.D.
Registration No.: 64,753
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant